Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Work In Process (2013 - 2015)

Iradimed (IRMD) reported Work In Process of $127460.0 for Q3 2015, up 39.38% year-over-year from $91448.0 in Q3 2014, and down 2.31% on a QoQ basis from $130477.0 in Q2 2015.

Iradimed (IRMD) has 3 years of Work In Process data on file, last reported at $127460.0 in Q3 2015.

  • Quarterly Work In Process rose 39.38% year-over-year to $127460.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $127460.0 (up 39.38% YoY) and the FY2014 annual result came in at $126188.0, up 780.16% from the prior year.
  • Work In Process retreated to $127460.0 in Q3 2015 per IRMD's latest filing, from $130477.0 in the prior quarter.
  • Across five years, Work In Process topped out at $181583.0 in Q1 2015 and bottomed at $14337.0 in Q4 2013.
  • The 3-year median for Work In Process is $126188.0 (2014), against an average of $107108.1.
  • The widest annual swing landed in 2014, when Work In Process surged 780.16%; it then soared 39.38% in 2015.
  • Tracing IRMD's Work In Process over 3 years: stood at $14337.0 in 2013, then surged by 780.16% to $126188.0 in 2014, then increased by 1.01% to $127460.0 in 2015.
  • Per Business Quant, the three latest IRMD Work In Process figures stand at $127460.0 (Q3 2015), $130477.0 (Q2 2015), and $181583.0 (Q1 2015).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Iradimed 1.17 Bn 1.11 Bn 16.81 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2015 127,460.00
Jun 30, 2015 130,477.00
Mar 31, 2015 181,583.00
Dec 31, 2014 126,188.00
Sep 30, 2014 91,448.00
Jun 30, 2014 78,264.00
Dec 31, 2013 14,337.00